These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

553 related items for PubMed ID: 9085323

  • 1. Lansoprazole: a comprehensive review.
    Zimmermann AE, Katona BG.
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [Abstract] [Full Text] [Related]

  • 2. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C.
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [Abstract] [Full Text] [Related]

  • 3. Proton pump inhibitors and acid-related diseases.
    Sachs G.
    Pharmacotherapy; 1997; 17(1):22-37. PubMed ID: 9017763
    [Abstract] [Full Text] [Related]

  • 4. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M, Pospai D, Forestier S, Vatier J, Vallot T.
    Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
    [Abstract] [Full Text] [Related]

  • 5. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
    Gremse DA.
    Expert Opin Pharmacother; 2001 Oct; 2(10):1663-70. PubMed ID: 11825309
    [Abstract] [Full Text] [Related]

  • 6. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
    Spencer CM, Faulds D.
    Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
    [Abstract] [Full Text] [Related]

  • 7. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A, Celikel CA, Ozdogan O, Tözün N, Ulusoy NB, Kalayci C.
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [Abstract] [Full Text] [Related]

  • 8. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
    Poynard T, Lemaire M, Agostini H.
    Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):661-5. PubMed ID: 8590162
    [Abstract] [Full Text] [Related]

  • 9. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD, Wilde MI.
    Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
    [Abstract] [Full Text] [Related]

  • 10. [Lansoprazol ++ : a new proton pump inhibitor].
    Baczek J, Laskowiec G.
    Pol Merkur Lekarski; 1998 Jun; 4(24):339-41. PubMed ID: 9771021
    [Abstract] [Full Text] [Related]

  • 11. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
    Barradell LB, Faulds D, McTavish D.
    Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
    [Abstract] [Full Text] [Related]

  • 12. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD, Markham A.
    Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
    [Abstract] [Full Text] [Related]

  • 13. Lansoprazole and omeprazole in the treatment of acid peptic disorders.
    Blum RA.
    Am J Health Syst Pharm; 1996 Jun 15; 53(12):1401-15. PubMed ID: 8781686
    [Abstract] [Full Text] [Related]

  • 14. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI.
    Ohara T, Morishita T, Suzuki H, Masaoka T, Ishii H.
    Hepatogastroenterology; 2004 Jun 15; 51(56):338-42. PubMed ID: 15086153
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group.
    Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM.
    Am J Gastroenterol; 1996 Sep 15; 91(9):1749-57. PubMed ID: 8792693
    [Abstract] [Full Text] [Related]

  • 16. pH, healing rate, and symptom relief in patients with GERD.
    Huang JQ, Hunt RH.
    Yale J Biol Med; 1999 Sep 15; 72(2-3):181-94. PubMed ID: 10780580
    [Abstract] [Full Text] [Related]

  • 17. An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
    Bown RL.
    Int J Clin Pract; 2002 Mar 15; 56(2):132-9. PubMed ID: 11926700
    [Abstract] [Full Text] [Related]

  • 18. [Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer].
    Kayser S, Flury R, Zbinden R, Fried M, Wirth HP.
    Schweiz Med Wochenschr; 1997 Apr 26; 127(17):722-7. PubMed ID: 9221483
    [Abstract] [Full Text] [Related]

  • 19. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
    Feldman M, Harford WV, Fisher RS, Sampliner RE, Murray SB, Greski-Rose PA, Jennings DE.
    Am J Gastroenterol; 1993 Aug 26; 88(8):1212-7. PubMed ID: 8101695
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ, Hunt RH.
    Best Pract Res Clin Gastroenterol; 2001 Jun 26; 15(3):355-70. PubMed ID: 11403532
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.